152
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Administration of glucocorticoids prior to liquid biopsy dramatically reduces the detection rate of MYD88 L265P mutation in cerebrospinal fluid of primary CNS lymphoma patients

, , , , , , , , , , , , & show all
Pages 1219-1222 | Received 29 Nov 2022, Accepted 28 Mar 2023, Published online: 18 Apr 2023

References

  • Watanabe J, Natsumeda M, Okada M, et al. High detection rate of MYD88 mutations in cerebrospinal fluid from patients with CNS lymphomas. J Clin Oncol Precis Oncol. 2019;3(3):1–13.
  • Watanabe J, Natsumeda M, Kanemaru Y, et al. Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma. Leuk Lymphoma. 2019;60(14):3587–3589.
  • Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, et al. The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematol Oncol. 2018;36(2):429–435.
  • Rimelen V, Ahle G, Pencreach E, et al. Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. Acta Neuropathol Commun. 2019;7(1):43.
  • Baraniskin A, Deckert M, Schulte-Altedorneburg G, et al. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br J Haematol. 2012;156(4):421–432.
  • Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–2487.
  • Yu X, Li W, Deng Q, et al. MYD88 L265P mutation in lymphoid malignancies. Cancer Res. 2018;78(10):2457–2462.
  • Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2016;42(3):279–290.
  • Önder E, Arıkök AT, Önder S, et al. Corticosteroid pre-treated primary CNS lymphoma: a detailed analysis of stereotactic biopsy findings and consideration of interobserver variability. Int J Clin Exp Pathol. 2015;8(7):7798–7808.
  • Scheichel F, Marhold F, Pinggera D, et al. Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study. BMC Cancer. 2021;21(1):754.
  • Okita Y, Narita Y, Miyakita Y, et al. Long-term follow-up of vanishing tumors in the brain: how should a lesion mimicking primary CNS lymphoma be managed? Clin Neurol Neurosurg. 2012;114(9):1217–1221.
  • Pistacchi M, Gioulis M, Sanson F, et al. Primary Central nervous system lymphoma in an immunocompetent patient: an unusual case of prolonged response to steroids. Neurol Sci. 2018;39(5):941–943.
  • Peng M, Chen C, Hulbert A, et al. Non-blood circulating tumor DNA detection in cancer. Oncotarget. 2017;8(40):69162–69173.
  • De Mattos-Arruda L, Mayor R, Ng CKY, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.
  • Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999;64(1):218–224.
  • Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.